R788 disodiumSyk inhibitor,ATP competitive and potent CAS# 1025687-58-4 |
- PRT062607 Hydrochloride
Catalog No.:BCC1869
CAS No.:1370261-97-4
- BAY 61-3606 dihydrochloride
Catalog No.:BCC1407
CAS No.:648903-57-5
- BAY 61-3606
Catalog No.:BCC1406
CAS No.:732983-37-8
- R406 (free base)
Catalog No.:BCC2553
CAS No.:841290-80-0
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 1025687-58-4 | SDF | Download SDF |
| PubChem ID | 25008120 | Appearance | Powder |
| Formula | C23H24FN6Na2O9P | M.Wt | 624.42 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Synonyms | Fostamatinib Disodium | ||
| Solubility | DMSO : 50 mg/mL (80.07 mM; Need ultrasonic) | ||
| Chemical Name | disodium;[6-[[5-fluoro-2-(3,4,5-trimethoxyanilino)pyrimidin-4-yl]amino]-2,2-dimethyl-3-oxopyrido[3,2-b][1,4]oxazin-4-yl]methyl phosphate | ||
| SMILES | CC1(C(=O)N(C2=C(O1)C=CC(=N2)NC3=NC(=NC=C3F)NC4=CC(=C(C(=C4)OC)OC)OC)COP(=O)([O-])[O-])C.[Na+].[Na+] | ||
| Standard InChIKey | HSYBQXDGYCYSGA-UHFFFAOYSA-L | ||
| Standard InChI | InChI=1S/C23H26FN6O9P.2Na/c1-23(2)21(31)30(11-38-40(32,33)34)20-14(39-23)6-7-17(28-20)27-19-13(24)10-25-22(29-19)26-12-8-15(35-3)18(37-5)16(9-12)36-4;;/h6-10H,11H2,1-5H3,(H2,32,33,34)(H2,25,26,27,28,29);;/q;2*+1/p-2 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | R788 (Fostamatinib) disodium, a prodrug of the active metabolite R406, is an inhibitor of Syk with IC50 of 41 nM. | |||||
| Targets | Syk | |||||
| IC50 | 41 nM | |||||
R788 disodium Dilution Calculator
R788 disodium Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.6015 mL | 8.0074 mL | 16.0149 mL | 32.0297 mL | 40.0372 mL |
| 5 mM | 0.3203 mL | 1.6015 mL | 3.203 mL | 6.4059 mL | 8.0074 mL |
| 10 mM | 0.1601 mL | 0.8007 mL | 1.6015 mL | 3.203 mL | 4.0037 mL |
| 50 mM | 0.032 mL | 0.1601 mL | 0.3203 mL | 0.6406 mL | 0.8007 mL |
| 100 mM | 0.016 mL | 0.0801 mL | 0.1601 mL | 0.3203 mL | 0.4004 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
R788, which is the prodrug of R406, is a potnet and selective Syk inhibitor. The spleen tyrosine kinase (Syk) plays a key role in the signaling of activating Fc receptors and the B-cell receptor (BCR).
In vitro: R406 was found to induce the apoptosis of the majority of examined DLBCL cell lines and could specifically inhibit both tonic- and ligand-induced BCR signaling (autophosphorylation of SYK525/526 and SYKdependent phosphorylation of the B-cell linker protein [BLNK]) [1].
In vivo: R788 effectively inhibits BCR signaling, demonstrating reduced proliferation and survival of the malignant B cells and significantly prolonged survival of the treated Eμ-TCL1 transgenic mouse. Moreover, the effect of R788 was found to be selective for the malignant clones, since no disturbance in the production of normal B lymphocytes was observed [2].
Clinical trial: In a phase II clinical trial, R788 treatment effectively improved American College of Rheumatology response rates in patients with eumatoid arthritis [3].
References:
[1] Chen L, Monti S, Juszczynski P, Daley J, Chen W, Witzig TE, Habermann TM, Kutok JL, Shipp MA. SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma. Blood. 2008 Feb 15;111(4):2230-7.
[2] Suljagic M, Longo PG, Bennardo S, Perlas E, Leone G, Laurenti L, Efremov DG. The Syk inhibitor fostamatinib disodium (R788) inhibits tumor growth in the Eμ- TCL1 transgenic mouse model of CLL by blocking antigen-dependent B-cell receptor signaling. Blood. 2010 Dec 2;116(23):4894-905.
[3] Bajpai M. Fostamatinib, a Syk inhibitor prodrug for the treatment of inflammatory diseases. IDrugs. 2009 Mar;12(3):174-85.
- 2,3,23-Trihydroxy-12-oleanen-28-oic acid
Catalog No.:BCN1638
CAS No.:102519-34-6
- (-)-Huperzine A
Catalog No.:BCN1057
CAS No.:102518-79-6
- SGI-1776 free base
Catalog No.:BCC2232
CAS No.:1025065-69-3
- Periglaucine B
Catalog No.:BCN7053
CAS No.:1025023-05-5
- Periglaucine A
Catalog No.:BCN5839
CAS No.:1025023-04-4
- GK921
Catalog No.:BCC8057
CAS No.:1025015-40-0
- Kushenol N
Catalog No.:BCN2984
CAS No.:102490-65-3
- RN 1747
Catalog No.:BCC7769
CAS No.:1024448-59-6
- Fmoc-Phg-OH
Catalog No.:BCC3312
CAS No.:102410-65-1
- Jasplakinolide
Catalog No.:BCC7485
CAS No.:102396-24-7
- AF-DX 116
Catalog No.:BCC6939
CAS No.:102394-31-0
- Glyburide
Catalog No.:BCC4784
CAS No.:10238-21-8
- Methyl lucidente G
Catalog No.:BCN8269
CAS No.:102607-20-5
- Ganoderic acid L
Catalog No.:BCN8204
CAS No.:102607-24-9
- Saprorthoquinone
Catalog No.:BCN3147
CAS No.:102607-41-0
- Pantoprazole
Catalog No.:BCC5432
CAS No.:102625-70-7
- SC-9
Catalog No.:BCC6646
CAS No.:102649-78-5
- SC-10
Catalog No.:BCC6643
CAS No.:102649-79-6
- RO-3
Catalog No.:BCC7548
CAS No.:1026582-88-6
- LB-100
Catalog No.:BCC5532
CAS No.:1026680-07-8
- Labd-13-ene-8,15-diol
Catalog No.:BCN5840
CAS No.:10267-31-9
- VX-222 (VCH-222, Lomibuvir)
Catalog No.:BCC2108
CAS No.:1026785-59-0
- H-Gln(Trt)-OH
Catalog No.:BCC2919
CAS No.:102747-84-2
- PSB 0788
Catalog No.:BCC7599
CAS No.:1027513-54-7
The Syk inhibitor fostamatinib disodium (R788) inhibits tumor growth in the Emu- TCL1 transgenic mouse model of CLL by blocking antigen-dependent B-cell receptor signaling.[Pubmed:20716772]
Blood. 2010 Dec 2;116(23):4894-905.
Inhibition of antigen-dependent B-cell receptor (BCR) signaling is considered a promising therapeutic approach in chronic lymphocytic leukemia (CLL), but experimental in vivo evidence to support this view is still lacking. We have now investigated whether inhibition of BCR signaling with the selective Syk inhibitor fostamatinib disodium (R788) will affect the growth of the leukemias that develop in the Emu-TCL1 transgenic mouse model of CLL. Similarly to human CLL, these leukemias express stereotyped BCRs that react with autoantigens exposed on the surface of senescent or apoptotic cells, suggesting that they are antigen driven. We show that R788 effectively inhibits BCR signaling in vivo, resulting in reduced proliferation and survival of the malignant B cells and significantly prolonged survival of the treated animals. The growth-inhibitory effect of R788 occurs despite the relatively modest cytotoxic effect in vitro and is independent of basal Syk activity, suggesting that R788 functions primarily by inhibiting antigen-dependent BCR signals. Importantly, the effect of R788 was found to be selective for the malignant clones, as no disturbance in the production of normal B lymphocytes was observed. Collectively, these data provide further rationale for clinical trials with R788 in CLL and establish the BCR-signaling pathway as an important therapeutic target in this disease.
